Range
- - -
Vol / Avg.
-/461K
Div / Yield
-
52 Wk
29.28 - 44.83
Mkt Cap
28.8B
Payout Ratio
-
Open
-
P/E
31.83
EPS
0.88
Shares
653.6M
Outstanding
653.6M
Total Float
-
Benzinga - Jun 3, 2021, 8:23AM
Benzinga - May 21, 2021, 9:10AM
Benzinga - May 5, 2021, 11:03AM
Benzinga - Apr 20, 2021, 6:50AM
Benzinga - Apr 19, 2021, 10:37AM
Benzinga - Feb 24, 2021, 5:27AM
Benzinga - Feb 23, 2021, 11:11AM
Benzinga - Feb 23, 2021, 11:10AM
Benzinga - Feb 23, 2021, 11:05AM
Benzinga - Jan 26, 2021, 9:10AM
Benzinga - Jan 19, 2021, 9:56AM
Benzinga - Jan 19, 2021, 7:01AM
Benzinga - Jan 15, 2021, 9:24AM
Benzinga - Jan 13, 2021, 9:23AM
Benzinga - Jan 4, 2021, 2:00PM
load more
Sector: Health Care.Industry: Biotechnology
Genmab is a Copenhagen-based cancer drug developer best known for its antibody technology platforms, DuoBody and HexaBody, and multiple myeloma drug Darzalex (daratumumab), which is partnered with Johnson & Johnson. The company is the creator of Tepezza for thyroid eye disease (partnered with Horizon) and Kesimpta for relapsing multiple sclerosis (partnered with Novartis) and has several pipeline candidates targeting other oncologic indications and autoimmune diseases.

Earnings

see more
Q2 2021Est.ActualSurprise
EPS
(EXPECTED)2021-08-11
REV
Q1 2021Est.ActualSurprise
EPS0.2302.690 2.4600
REV207.510M256.280M48.770M

Analyst Ratings

see more
DateAnalyst FirmAnalyst NameActionRatingAction Price Prior Price Target

Related Companies

TickerCompanyChg %Mkt Cap
GMABGenmab0%28.8B

Genmab Frequently Asked Questions

Q

How do I buy Genmab (GMAB) stock?

A

You can purchase shares of Genmab (NASDAQ: GMAB) through any online brokerage.

View our list of the best stock brokerages.

Q

Who are Genmab's (GMAB) competitors?

A

Other companies in Genmab’s space includes: Exact Sciences (NASDAQ:EXAS), Neurocrine Biosciences (NASDAQ:NBIX), Amgen (NASDAQ:AMGN), BioNTech (NASDAQ:BNTX) and Natera (NASDAQ:NTRA).

Q

What is the target price for Genmab (GMAB) stock?

A

The latest price target for Genmab (NASDAQ: GMAB) was reported by Morgan Stanley on April 19, 2021. The analyst firm set a price target for 37.00 expecting GMAB to fall to within 12 months (a possible -16.18% downside). 17 analyst firms have reported ratings in the last year.

Q

Current Stock Price for Genmab (GMAB)?

A

The stock price for Genmab (NASDAQ: GMAB) is $44.14 last updated Mon Jun 14 2021 20:00:03 GMT+0000 (Coordinated Universal Time).

Q

Does Genmab (GMAB) pay a dividend?

A

There are no upcoming dividends for Genmab.

Q

When is Genmab (NASDAQ:GMAB) reporting earnings?

A
Genmab’s Q2 earnings are confirmed for after-market on August 11, 2021.
Q

Is Genmab (GMAB) going to split?

A

There is no upcoming split for Genmab.

Q

What sector and industry does Genmab (GMAB) operate in?

A

Genmab is in the Consumer Discretionary sector and Multiline Retail industry. They are listed on the NASDAQ.